Cancer & In Silico Oncology Task Force
Mission: Accelerate, optimize and personalize cancer treatment through the development, clinical validation and clinical translation of in silico methods
Cancer is such a complex global threat that the European Commission has included it in the list of the five prioritized research missions of the Horizon Europe research and innovation programme for the years 2021-2027.
As a branch of the Avicenna Research & Technology WG, the Cancer and In Silico Oncology TF has the objective to accelerate, optimize and personalize cancer treatment through the development, clinical validation and clinical translation of in silico methods.
Goals
- Develop clinically driven and overseen digital twins of tumour growth and tumour and organism response to cancer treatment interventions.
- Ensure trustworthiness, explainability, robustness, stability and good quality of component interconnection for all underying mechanistic and/or AI and/or hybrid models.
- Technically and clinically validate cancer digital twins through formal clinical studies, including clinical trials.
- Translate cancer digital twins into clinical practice, following certification
- Monitor and evaluate the clinical use of certified cancer digital twins and further exploit the latter for in silico clinical trials and broader clinical research.
